NeuroSigma, Inc. Retains CCG Investor Relations
LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign.
"We look forward to working closely with CCG to establish and enhance our profile in the investment community and with all our stakeholders," said Lodwrick M. Cook, Chairman of NeuroSigma.
"Given CCG's track record of professional experience representing a wide spectrum of high-growth, U.S. companies, we are confident that our new partnership will help us achieve those goals," added Dr. Leon Ekchian, President and CEO of NeuroSigma.
Founded by experts in business management and the healthcare industry, NeuroSigma has a growing pipeline of therapies in clinical trials targeting epilepsy, depression, post-traumatic stress disorder (PTSD), and obesity, among others. NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials at the University of California, Los Angeles (UCLA) and is currently utilizing two distinct therapy platforms:
Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at UCLA and exclusively licensed to NeuroSigma.
Deep Brain Stimulation (DBS) – NeuroSigma is supporting the development of new therapies for this platform, which was originally pioneered in France for the treatment of essential tremor and Parkinson's disease.
"We are very pleased to be working with NeuroSigma," said William Coffin, Chairman of CCG Investor Relations. "At a time when translating important medical research from 'lab bench to bedside' has never been more valuable, NeuroSigma is providing that expertise, working with the very best at institutions like UCLA and bringing their pioneering work to the marketplace for commercialization. The Company is initially focused on several very important conditions, including epilepsy, which affects 3 million people in the United States and over 50 million worldwide, and major depression, affecting over 18 million American adults and over 120 million worldwide. With its current team and strong development processes in place, the Company is well positioned for the future."
NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice. Currently we have a specific focus on neuromodulation. NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS). NeuroSigma has amassed a significant intellectual property portfolio, primarily licensed from the University of California, Los Angeles on a world-wide exclusive basis, including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS. More information about NeuroSigma is online at http://www.neurosigma.com/
About CCG Investor Relations
CCG is a leading global investor relations and strategic communications consulting firm. In business for more than 30 years, the agency provides a complete range of strategic and investor communications, through our global network to over 100 clients across multiple capital markets. CCG has been awarded a number of industry honors for its handling of complex investor relations communications matters. The agency's corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, London, and Tel Aviv. For further information, contact CCG directly, or visit the Company's web site at http://www.ccgir.com/
SOURCE NeuroSigma, Inc.